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Abstract
Background: Metastases to the pancreas are rare, accounting for less then 2 % of all pancreatic malignancies.
However, both the benefit of extended tumor resection and the ideal oncological approach have not been
established for such cases; therefore, we evaluated patients with metastasis to the pancreas who underwent
pancreatic resection.
Methods: Between 1994 and 2012, 676 patients underwent pancreatic surgery in our institution. We retrospectively
reviewed patients’ medical records according to survival, and surgical and non-surgical complications. Student’s t-test
and the log-rank test were used for statistical analysis.
Results: Eighteen patients (2.7 %) received resection for pancreatic metastases (12 multivisceral resections and
6 standard resections). The pancreatic metastases originated from renal cell carcinoma (n = 10), malignant melanoma
(n = 2), neuroendocrine tumor of the ileum (n = 1), sarcoma (n = 1), colon cancer (n = 1), gallbladder cancer (n = 1),
gastrointestinal stromal tumor (n = 1), and non-small cell lung cancer (n = 1). The median time between primary
malignancy resection to metastasectomy was 83 months (range, 0–228 months). Minor surgical complications
(Grade I-IIIa) occurred in six patients (33.3 %) whereas major surgical complications (Grade IIIb-V) occurred in three
patients (16.6 %). No patients died during hospitalization. The median follow-up was 76 months (range, 10–165
months). One-year, 3-year and 5-year survival for standard resection versus multivisceral resection was 83, 50, and
56 % versus 83, 66, and 50, respectively. Twelve patients died after a median of 26 months (range, 5–55 months).
Conclusions: A surgical approach with curative intent is justified in select patients suffering from metastases to
the pancreas and offers good long-term survival. The resection of pancreatic metastases of different tumor types
was associated with favorable morbidity and mortality when compared with resection of the primary pancreatic
malignancies. Our findings also demonstrated that multivisceral resection was feasible, with acceptable long term
outcomes, even though morbidity rates tended to be higher after multivisceral resection than after standard resection.
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Background
Metastases to the pancreas are rare and account only for
1–2 % of all pancreatic malignancies [1]. Most primaries
that spread to the pancreas are renal cell carcinomas
(RCC), lung cancers, malignant melanomas, and malig-
nancies of the gastrointestinal tract [2, 3]. However, at
the time of diagnosis, patients often present with
widespread systemic disease and therefore, no curative
treatment is applicable. Several studies have demon-
strated survival benefit and improved quality of life
after complete metastasectomy for isolated lung or
liver metastases [4, 5]. Therefore, extended surgical
intervention is a well-established approach in a multi-
disciplinary concept for select patients suffering from
colorectal or pulmonary metastases in the liver [6].
However, extended surgery for pancreatic metastasectomy
is rare and remains debatable as there have been few
studies on the procedure, all of which have reported
controversial results [7–9]. Patients with localized
extrapancreatic disease appear to be suitable for pan-
creatic resection but the ideal oncological approach
has not been established and the benefit of multivisc-
eral resection (MVR) remains undetermined. Our aim
was to assess the frequency and feasibility of MVR
for metastases to the pancreas. We also analyzed the
influence of MVR on perioperative and long-term
outcomes compared with standard resection.
Methods
We retrospectively analyzed the medical records of
patients who underwent pancreatic resection at the
Department of Visceral, Transplant, Thoracic, and
Vascular Surgery, University Hospital Leipzig, Leipzig,
Germany, between 1994 and 2012.
For this study ethical approval was obtained from
the institutional local ethical committee (AZ 318-14-
06102014, Ethical committee of the University Clinic
Leipzig, Leipzig). Due to the retrospective design of
the study and accordingly national guidelines, the
local ethic committee confirmed, that informed con-
sent was not necessary from participants.
All patients were operated on with curative intent. We
included patients with extrapancreatic spread in this
study only when extrapancreatic disease appeared to be
resectable, and we excluded patients with primary tu-
mors that had infiltrated the pancreas through direct
extension.
We assessed the following patient characteristics: sex,
age, body mass index, preoperative symptoms, comor-
bidities, type of resection, duration of operation, re-
quired units of fresh frozen plasma and/or packed red
blood cells, median length of stay on the intensive care
unit, total length of stay, time between surgery for the
primary tumor and pancreatic resection, postoperative
morbidity according to Clavien-Dindo classification [10],
presence of pancreatic fistulae according to the Inter-
national Study Group for Pancreatic Fistula criteria [11],
hospital mortality defined as death within the first
60 days after resection, overall survival rate, disease-free
survival, and histopathological data. Patients who died
within the first 90 days after resection were excluded
from further statistical analysis. MVR was defined as re-
section of one additional organ, excluding the spleen.
Statistics
Data are presented as median (range) unless otherwise
specified. Statistical differences between groups were
determined by Student’s t-test. Student’s t-test and the
log-rank test were used to analyze continuous variables
and overall survival excluding in-hospital mortality, re-
spectively. All statistical analyses were performed with
SPSS for Windows (version 12.0, SPSS Inc., Chicago,
IL, USA).
Results
Patient characteristics and preoperative symptoms
Between 1994 and 2012, 676 patients were scheduled for
pancreatic surgery, of which 18 (2.6 %) received resec-
tion for metastatic disease of the pancreas (Table 1).
Eight of the patients were men and 10 were woman
with a median age of 65 years (range, 22–75 years)
and a median body mass index of 25.4 kg/m2 (range,
18–31 kg/m2). Four patients (22.2 %), had diabetes
mellitus type II and 13 (72.2 %) patients received
medication for high blood pressure (Table 2). At the
time of diagnosis of pancreatic metastases, eight patients
(44.4 %) had one or more tumor-related symptoms includ-
ing weight loss (n = 8), abdominal pain (n = 8), decrease in
general performance (n = 5), obstructive jaundice (n = 2),
or absence of appetite (n = 1). Ten patients (55.5 %)
had no specific symptoms and the diagnosis of pancreatic
metastases was obtained through routine follow-up
examinations.
Primary tumor characteristics
The majority of pancreatic metastases originated from
renal cell carcinoma (n = 10; 55.5 %), malignant melan-
oma (n = 2), and neuroendocrine tumor of the ileum
(n = 1). Other primaries included sarcoma (n = 1),
colon cancer (n = 1), gallbladder cancer (n = 1), gastro-
intestinal stromal tumor (n = 1), and non-small cell
lung cancer (n = 1). Metastases to the pancreas were
located mainly in the pancreatic head (n = 10)
followed by the total pancreas (n = 3) and the cauda
region (n = 3). In two patients, metastases were simul-
taneously located in the corpus and cauda region.
Eleven patients (61 %) had simultaneous metastases in
other organs and seven of these patients underwent
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Table 1 Patient characteristics








1 RCC Head (sync.) 0 PPPD + Nephrectomy no no/alive
2 Lung-Cancer Cauda (metac.) 83 DP + Gastrectomy + Splenectomy + vertebral body resection Vertebral body (s) no/TRD
3 RCC Head (metac.) 142 PPPD no no/Non-TRD
4 RCC Head (sync.) 0.8 PPPD no Local recurrence/alive
5 RCC Head/Corpus/Cauda (metac.) 120 Enucleation in pancreatic head + DP + Splenectomy Lung (s) Thyroid/TRD
6 RCC Head/Corpus/Cauda (metac.) 132 TP + Spleenectomy + distal Gastrectomy Thyroid (s) no/TRD
7 Gallblader-Cancer Head (sync.) 0 PPPD + Liver resection (SII SIII) Liver (a) yes/TRD
8 RCC Corpus/Cauda (sync.) 17 DP + Spleen + Colon +Jejunom Pulmo (s) no/TRD
9 GIST Head (metac.) 34 PPPD + Hemicolectomy Liver (a) yes/alive
10 RCC Head (metac.) 106 Whipple no Lung/TRD
11 Sarcoma Head (sync.) 0 Whipple + Hemihepatectomy + Hemicolectomy Liver (s) Liver/TRD
12 RCC Head/Corpus/Cauda (metac.) 66 TP + Spleen no Cerebral/TRD
13 Melanoma Head/Corpus/Cauda (metac.) 90 TP + Segemental liver resection Liver (a) Liver/alive
14 RCC Cauda (metac.) 123 DP Pulmo (s) Thyroid/TRD
15 Melanoma Head (metac.) 228 PPPD + Hemihepatectomy Liver (a) Liver/TRD
16 RCC Head (sync.) 0 DP + Spleen + Nephrctomy no no/alive
17 Colon-Cancer Head (metac.) 29 PPPD + Liver resection (Lobus caudatus) Liver (s) no/alive
18 NET Ileum Head (sync.) 78 PPPD + Jejunum Jejunum (s) no/alive
sync. indicates synchronous metastases to the pancreas; metac. indicates metachronous metastases to the pancreas; * interval from resection of primary tumor to resection of pancreatic metastasis; □ excluding
pancreas (a, after; s, synchronous; p, prior); † at time of study; RCC indicates renal cell carcinoma; NET indicates neuroendocrine tumor; PPPD indicates pylorus-preserving pancreaticoduodenectomy; DP indicates distal












simultaneous resection of the extrapancreatic masses. The
other four patients received a subsequent procedure
(metastasectomy of the lungs in three cases and one thy-
roidectomy). In four patients, the diagnosis of pancreatic
metastases coincided with that of the primary malignancy,
which was RCC in all cases. In three of these patients, pri-
mary tumor and metastatic resection was performed as
one procedure. In one patient, an intraoperative biopsy of
the pancreatic head during tumor-nephrectomy con-
firmed metastatic disease and metastasectomy was per-
formed four weeks later. In three patients (30 %) with
RCC multifocal lesions in the resected specimens were
detected.
Surgical procedures
The median time between resection of the primary ma-
lignancies to resection of the pancreatic metastases was
83 months (range, 0–228 months). The most frequently
used surgical procedures were Whipple-procedure/pyl-
orus-preserving pancreaticoduodenectomy (PPPD) in 10
patients and distal pancreatectomy (DP) in five patients.
In four patients, DP was performed with and, in one
patient, without splenectomy. In three patients, total
pancreatectomy was performed, with simultaneous
splenectomy in two cases. MVR was performed in 12
(66.6 %) patients. Five patients who received Whipple-
procedure/PPPD or total pancreatectomy also required
additional liver resection to remove synchronous extra-
pancreatic metastases. Two of these patients underwent
additional bowel resection and three patients received
additional gastric or bowel resection. In two patients who
underwent PPPD or DP, simultaneous nephrectomy was
performed and one patient received simultaneous verte-
bral body resection for solitary bone metastasis. The me-
dian operation time for all procedures was 322 min
(range, 193–591 min). Ten patients received intraopera-
tive fresh frozen plasma (median 3, range 0–18 units)
and/or packed red blood cells (median 2, range, 0–10
units). Microscopically-free resection margins (R0) were
achieved in 77.7 % of the patients.
Perioperative outcome
Length of stay in the intensive care unit and total length
of stay were 2 days (range, 1–50 days) and 21.5 days
(range, 12–55 days), respectively (Table 3). No patients
died during hospitalization. Postoperative complications
occurred in 11 patients (61.1 %), of which 81 % were
surgical and 18 % were non-surgical complications.
Minor surgical complications (Grade I-IIIa, n = 6) were:
new onset of diabetes in two patients; wound infection
Table 2 Demographic data
Characteristics Total (n = 18) Standard Resection (n = 6) Multivisceral resection (MVR; n = 12) p-value*
Age (median; Range) 65 (22–75) 70 (49–75) 58 (22–72) 0.074
Gender (%)
Female 10 (55.6) 4 (22.2) 6 (33.3) 0.548
Male 8 (44.4) 2 (11.1) 6 (33.3) 0.548
BMI (median; Range) 25.4 (18–31.1) 26 (21.7–30.4) 24.4 (18–31.1) 0.264
Comorbidities (%)
Diabetes mellitus 4 (22.2) 2 (11.1) 2 (11.1) 0.932
Arterial hypertension 13 (72.2) 5 (33.3) 8 (44.4) 0.817
Metabolic syndrome 3 (16.7) 1 (5.6) 2 (11.1) 0.932
COPD* 2 (11.1) 0 (0) 2 (11.1) 0.104
CAD 5 (27.8) 1 (5.6) 4 (22.2) 0.374
Preoperative symptoms (%)
Asymptomatic 10 (55.6) 4 (22.2) 6 (33.3) 0.548
Symptomatic
Weight loss 8 (44.4) 3 (16.7) 5 (33.3) 0.984
Abdominal pain 7 (38.9) 3 (16.7) 4 (33.3) 0.682
obstructive jaundice 2 (11.1) 0 (0) 2 (11.1) 0.103
decrease in general performance 3 (16.7) 1 (5.6) 2 (11.1) 0.742
absence of appetite 1 (5.6) 1 (5.6) 0 (0) 0.170
Sleep hyperhidrosis 1 (5.6) 0 (0) 1 (5.6) 0.166
New onset of diabetes 1 (5.6) 0 (0) 1 (5.6) 0.166
COPD indicates chronic obstructive pulmonary disease; CAD indicates coronary artery disease
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(n = 2), which was managed conservatively; and pancre-
atic fistula grade B with prolonged use of abdominal
drainage (n = 2). Major surgical complications (Grade
IIIb-V, n = 3) were: leakage from the hepaticojejunost-
omy site with the need for relaparotomy, bowel perfor-
ation with the need for relaparotomy, biliary leakage
after combined liver and pancreas resection that had to
be treated with an interventional drain, and a wound
infection that required re-operation under general
anesthesia, with each complication occurring in one
case. Major non-surgical complications (Grade IIIb-V,
n = 2) occurred in two patients and both developed
pneumonia requiring readmission to the intensive care
unit.
Follow-up and survival
No patient was lost to follow-up and the median follow-
up time was 76 months (range, 10–165 months) with 12
patients dying after a median of 26 months (range, 5–55
months). Death was tumor-related in 11 cases and non-
tumor-related in one case. During follow-up, nine pa-
tients suffered from extrapancreatic recurrence. Five
patients received further surgical treatment including
thyroidectomy, liver resection, or metastasectomy of the
lungs. In one patient, cerebral metastasis was treated by
stereotactic irradiation. Local recurrence of pancreatic
disease was seen in one patient and was successfully
controlled by total resection of the pancreatic remnant.
In our sample, the time interval between resection of
the primary malignancy and detection of metastatic dis-
ease did not correlate significantly with overall survival
after resection of the pancreatic metastases. Kaplan-
Meier curve for survival with standard resection versus
MVR are shown in Fig. 1. One-, 3- and 5-year survival
for standard resection versus MVR was 83, 50, and 56 %,
versus 83, 66, and 50 %, respectively.
Discussion
Surgical interventions for metastatic disease have in-
creased over the last decade, concurrent with considerable
Table 3 Perioperative data
Data Total (n = 18) StandardResection (n = 6) Multivisceral resection (n = 12) p-Value
Operative Data
Length of operation (min) 322 (193–591) 261 (193–462) 346 (216–591) 0.137
FFPs and/or pRBCs 3 (0–18) 2 (0–10) 3 (0– 3) 1 (0–8) 3 (0–18) 4 (1–10) 0.291/0.838
Perioperative Data
LOS-ICU 2 (1–50) 1 (1–3) 3 (1–50) 0.205
T-LOS 21 (12–55) 20 (16– 2) 23 (12–55) 0.898
Time interval* 72 (0–228) 113 (0–142) 31.5 (0–228) 0.259
Follow-up 76 (10–165) 59 (28–95) 53 (10–165) 0.104
1-year/3-year/5-year survival 84/66/55 83/50/56 83/66/50
Histopathological data
RO/R1/R2 15/3/0 (83.3/16.7/0) 7/0/0 (38.9/0/0) 8/3/0 (44.4/16.7/0) 0.081
Negative/positive LN 13/5 (72.2/27.8) 6/1 (33.3/5.6) 7/4 (38.9/22.2) 0.278
Postoperative Complications (Clavien-Dindo classification)
Non-Surgical related complications
Minor (Grade I-IIIa) 0 (0) 0 (0) 0 (0) 0
Major (Grade IIIb – IV) 2 (11.1) 1 (5.6) 1 (5.6) 0.681
Surgical related complications
Minor (Grade I-IIIa) 6 (33.3) 2 (11.1) 4 (22.2) 0.781
Major (Grade IIIb – IV) 3 (16.7) 1 (5.6) 2 (11.1) 0.932
Overall Morbidity
Mortality (60 days) 0 (0) 0 (0) 0 (0) 0
Overall-Mortality
Follow up
Local recurrence 1 (5.6) 1 (5.6) 0 (0) 0.166
Extrapancreatic Recurrence 9 (50) 4 (22.2 5 (33.3) 0.565
Further surgical interventions 6 (33.3) 2 (11.1) 4 (22.2) 0.781
FFP, fresh frozen plasma; pRBC, packed red blood cells; LOS-ICU, length of stay in intensive care unit; T-LOS; total length of stay
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improvement in quality of life and long-term survival of
up to 10 years following resection for the most common
(liver or lung) metastases [12, 13]. As a result, surgical re-
section of metastases is now an integral part of a multidis-
ciplinary oncological approach [6]. In contrast, metastases
to the pancreas are uncommon and the majority of pa-
tients present with no specific symptoms [14] and with
non-resectable widespread disease at the time of diagnosis.
However, in cases of isolated disease, surgical intervention
may be beneficial in terms of overall survival, even in pa-
tients with localized extrapancreatic metastases, and in
terms of the need for MVR to obtain complete tumor-free
resection margins.
Based on our experience, surgical intervention is justi-
fied in select patients diagnosed with metastases to the
pancreas. Our data showed that surgical resection for
pancreatic metastases is feasible and provides good long
term results, even in patients undergoing MVR. Peri-
operative morbidity and in-hospital mortality were
comparable to studies evaluating standard pancreatic
resection for primary malignancies [15]. In our study,
morbidity after MVR tended to be higher than after
standard resection. However, MVR for pancreatic me-
tastases should not be considered an absolute contra-
indication for surgery, because our results indicated
equivalent overall survival in the MVR group.
The limitations of our study are the small cohort and
the absence of a control group treated by other thera-
peutic strategies. Therefore, general recommendations
cannot be made based on our data, even though
complete resection (R0) is generally considered a good
prognostic marker for patients’ overall survival [16]. For
instance, long-term survival of 10 years can be seen after
complete resection of colorectal liver metastases, which
emphasizes the importance of this therapeutic option
[12]. In our study, the rate of microscopically-free resec-
tion margins (77.7 %) did not differ from other studies
reporting positive resection margins for pancreatic can-
cer of 17–30 % [17–19].
Because of the high incidence of metastatic disease
originating from RCC, the most valid conclusions can be
provided for this tumor type. Consequently, most re-
ported data refer to RCC and are comparable with our
results in terms of incidence and overall survival [1, 8, 20].
In our study, 10 patients (55.5 %) had pancreatic metasta-
ses from RCC and the overall survival of this subgroup
was 60 %. In a recently published review, Tanis et al. re-
ported a 5-year survival rate of 72.6 % in 311 cases follow-
ing pancreatic surgery for RCC metastases [21]. In this
context, time of metastatic onset is discussed as a prog-
nostic marker for long-term survival. A small number of
studies have observed a trend to better overall survival in
patients with long disease-free interval when evaluating
primary tumor resection and onset of metastases to the
pancreas. We did not see a similar effect in our patients
because overall survival did not differ significantly be-
tween patients with longer disease-free interval. These
findings are supported by the results of a meta-analysis
which identified 15 studies addressing pancreatic
metastasectomy for RCC [1]. In the univariate analysis,
time from resection of the primary tumor did not affect
overall survival.
Many changes have been made, regarding the onco-
logical treatment for metastatic RCC. Individualized im-
munotherapy based on immunoreactive cytokines and/
or antiangiogenetic agents (e.g. bevacizumab, sunitinib,
Fig. 1 Kaplan–Meier survival curve showing survival for patients who underwent standard resection (solid line) versus multivisceral resection
(dotted line) (in months)
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and sorafenib) have showed encouraging results. There-
fore, surgical resection should not be considered as the
only therapeutic option: An interdisciplinary approach
including visceral surgeons, urologists and oncologists
should be performed for the treatment against pancre-
atic metastases to obtain sufficient synergistic antitumor
effects. However, the best way to combine surgery with
oncological treatment has to be evaluated addressed by
future studies.
Pancreatic metastases can occur after a long disease-
free interval, with a median time between resection of
the primary tumor and detection of pancreatic metasta-
ses of 72 months (range, 0–228 months). This biological
tumor behavior reflects the importance of a prudent
long-term follow-up in these patients, even if specific
symptoms are missing. This point is supported by our
findings, which revealed that only 44.4 % of the patients
had specific symptoms. We recommend that regular
follow-up including radiological imaging should be per-
formed even after a long disease-free interval.
Very few data are available regarding the potential im-
pact of MVR for pancreatic metastases on morbidity and
mortality because of the low proportion of patients with
MVR in most of the published studies [20]. However, in
our study, the majority of patients (66.6 %) were treated
by a multivisceral approach. In a retrospective analysis,
Strobel et al. compared patients who received either
standard resection or MVR for pancreatic metastases of
different tumor types [22]. The authors reported no sig-
nificant difference for morbidity and mortality between
groups, although morbidity in the MVR group tended to
be higher. Also, the majority of complications were sur-
gical, with one patient dying in each group. These results
are comparable to our results where the majority of
postoperative complications were also surgical. We also
saw that major surgical complications occurred more
frequently in the MVR group, although this result was
not statistically significant. Because of its potentially
beneficial impact on long-term survival, we do not con-
sider that MVR is an absolute contraindication but that
the increased operative risk should be considered in the
decision making process. The overall morbidity in our
study was not increased compared with the reported
morbidity rate for resection of primary pancreatic malig-
nancies of up to 58.5 %, even though major surgical
complications occurred more frequently in our study
[15]. This might be attributable to the high proportion
of patients who underwent MVR.
During our study follow-up, only one patient suf-
fered from tumor recurrence in the pancreas and this
was successfully treated by resection of the pancreatic
remnant without further tumor recurrence. This might be
interpreted as a sign of good local tumor control and is
supported by other studies [22].
In total, nine of our patients (50 %) developed extra-
pancreatic recurrence, of which five (33.3 %) had under-
gone previous MVR. Four patients received primarily
combined liver and pancreas resection for metastases of
sarcoma or gallbladder cancer (n = 1 for each cancer)
and for metastases of malignant melanoma in two cases.
In the latter patients, hepatic recurrence occurred and
further surgical intervention was performed in one pa-
tient, who is still alive. These results are consistent with
other reports showing a survival rate of 50 % after liver
resection for malignant melanoma [23]. Therefore, the
type of the primary tumor should also be considered
when deciding on surgery and the patient should be in-
formed of the risk of recurrence.
Conclusions
A surgical approach with curative intent is justified in
select patients suffering from metastases to the pan-
creas and offers good long-term survival. Our results
showed that resection of pancreatic metastases of dif-
ferent tumor types was associated with favorable mor-
bidity and mortality when compared with resection of
the primary pancreatic malignancies. Our findings also
demonstrated that MVR was feasible, with acceptable
long term outcomes, even though morbidity tended to
be higher than with standard resection.
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